Genetic spectrum and clinical correlates of somatic mutations in aldosterone-producing adenoma

Hypertension

Volumn 64, Issue 2, 2014, Pages 354-361

  Fernandes Rosa, Fabio Luiz ^a,b,c   Williams, Tracy Ann ^d   Riester, Anna ^e   Steichen, Olivier ^f   Beuschlein, Felix ^e   Boulkroun, Sheerazed ^a,b   Strom, Tim M ^g,h   Monticone, Silvia ^d   Amar, Laurence ^a,b,c   Meatchi, Tchao ^a,b,c   Mantero, Franco ⁱ   Cicala, Maria Verena ⁱ   Quinkler, Marcus ^j   Fallo, Francesco ⁱ   Allolio, Bruno ^k   Bernini, Giampaolo ^l   MacCario, Mauro ^d   Giacchetti, Gilberta ^m   Jeunemaitre, Xavier ^a,b,c   Mulatero, Paolo ^d   Reincke, Martin ^e   Zennaro, Maria Christina ^a,b,c   more..

^a PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d UNIVERSITY OF TURIN   (Italy)

^e UNIVERSITY OF MUNICH   (Germany)

^f SORBONNE UNIVERSITÉ   (France)

^g INSTITUTE OF EPIDEMIOLOGY   (Germany)

^h TECHNICAL UNIVERSITY OF MUNICH   (Germany)

ⁱ UNIVERSITY OF PADOVA   (Italy)

^j CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^k UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^l UNIVERSITY OF PISA   (Italy)

^m OSPEDALI RIUNITI   (Italy)

more..

Author keywords

adrenal cortex; aldosterone; aldosteronism; mineralocorticoids; mutation; potassium channels

Indexed keywords

ALDOSTERONE SYNTHASE; ATP1A1 PROTEIN; ATP2B3 PROTEIN; CACNA1D PROTEIN; CYP11B1 PROTEIN; KCNJ 5 PROTEIN; POTASSIUM; PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; EXOME; EXON; FEMALE; FOLLOW UP; GENE EXPRESSION; GENETIC SCREENING; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION STRUCTURE; POTASSIUM BLOOD LEVEL; PREVALENCE; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; SOMATIC MUTATION; SYSTOLIC BLOOD PRESSURE;

ADRENAL CORTEX; ALDOSTERONE; ALDOSTERONISM; MINERALOCORTICOIDS; MUTATION; POTASSIUM CHANNELS;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL ADENOMA; ADULT; AGE FACTORS; ALDOSTERONE; CALCIUM CHANNELS, L-TYPE; FEMALE; G PROTEIN-COUPLED INWARDLY-RECTIFYING POTASSIUM CHANNELS; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERALDOSTERONISM; MALE; MIDDLE AGED; MUTATION; PLASMA MEMBRANE CALCIUM-TRANSPORTING ATPASES; POTASSIUM; SEX FACTORS; SODIUM-POTASSIUM-EXCHANGING ATPASE;

EID: 84904465517     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.03419     Document Type: Article

References (27)

1. Rossi GP, Bernini G, Caliumi C, et al; PAPY Study Investigators. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006;48:2293-2300.
2. Hannemann A, Bidlingmaier M, Friedrich N, et al. Screening for primary aldosteronism in hypertensive subjects: results from two German epidemiological studies. Eur J Endocrinol. 2012;167:7-15.
3. Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, Gomez-Sanchez CE, Veglio F, Young WF Jr. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab. 2004;89:1045-1050.
4. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321.
5. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11-21.
6. Savard S, Amar L, Plouin PF, Steichen O. Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. Hypertension. 2013;62:331-336.
7. Mulatero P, Monticone S, Bertello C, Viola A, Tizzani D, Iannaccone A, Crudo V, Burrello J, Milan A, Rabbia F, Veglio F. Long-term cardio-and cerebrovascular events in patients with primary aldosteronism. J Clin Endocrinol Metab. 2013;98:4826-4833.
8. Amar L, Plouin PF, Steichen O. Aldosterone-producing adenoma and other surgically correctable forms of primary aldosteronism. Orphanet J Rare Dis. 2010;5:9.
9. Bayliss DA, Barrett PQ. Emerging roles for two-pore-domain potassium channels and their potential therapeutic impact. Trends Pharmacol Sci. 2008;29:566-575.
10. Choi M, Scholl UI, Yue P, et al. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science. 2011;331:768-772.
11. Boulkroun S, Beuschlein F, Rossi GP, et al. Prevalence, clinical, and molecular correlates of KCNJ5 mutations in primary aldosteronism. Hypertension. 2012;59:592-598.
12. Beuschlein F, Boulkroun S, Osswald A, et al. Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. Nat Genet. 2013;45:440-444, 444e1.
13. Oki K, Plonczynski MW, Luis Lam M, Gomez-Sanchez EP, Gomez-Sanchez CE. Potassium channel mutant KCNJ5 T158A expression in HAC-15 cells increases aldosterone synthesis. Endocrinology. 2012;153:1774-1782.
14. Azizan EA, Poulsen H, Tuluc P, et al. Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension. Nat Genet. 2013;45:1055-1060.
15. Scholl UI, Goh G, Stölting G, et al. Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. Nat Genet. 2013;45:1050-1054.
16. Küpers EM, Amar L, Raynaud A, Plouin PF, Steichen O. A clinical prediction score to diagnose unilateral primary aldosteronism. J Clin Endocrinol Metab. 2012;97:3530-3537.
17. Williams TA, Monticone S, Schack VR, et al. Somatic ATP1A1, ATP2B3, and KCNJ5 mutations in aldosterone-producing adenomas. Hypertension. 2014;63:188-195.
18. Letavernier E, Peyrard S, Amar L, Zinzindohoué F, Fiquet B, Plouin PF. Blood pressure outcome of adrenalectomy in patients with primary hyperaldosteronism with or without unilateral adenoma. J Hypertens. 2008;26:1816-1823.
19. Reincke M, Rump LC, Quinkler M, Hahner S, Diederich S, Lorenz R, Seufert J, Schirpenbach C, Beuschlein F, Bidlingmaier M, Meisinger C, Holle R, Endres S; Participants of German Conn's Registry. Risk factors associated with a low glomerular filtration rate in primary aldosteronism. J Clin Endocrinol Metab. 2009;94:869-875.
20. Mulatero P, Monticone S, Veglio F. Diagnosis and treatment of primary aldosteronism. Rev Endocr Metab Disord. 2011;12:3-9.
21. Rossi GP. Diagnosis and treatment of primary aldosteronism. Endocrinol Metab Clin North Am. 2011;40:313-332, vii.
22. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young WF Jr, Montori VM; Endocrine Society. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93:3266-3281.
23. Catterall WA. Signaling complexes of voltage-gated sodium and calcium channels. Neurosci Lett. 2010;486:107-116.
24. Neville AM, O'Hare MJ. Histopathology of the human adrenal cortex. Clin Endocrinol Metab. 1985;14:791-820.
25. Azizan EA, Lam BY, Newhouse SJ, Zhou J, Kuc RE, Clarke J, Happerfield L, Marker A, Hoffman GJ, Brown MJ. Microarray, qPCR, and KCNJ5 sequencing of aldosterone-producing adenomas reveal differences in genotype and phenotype between zona glomerulosa-and zona fasciculatalike tumors. J Clin Endocrinol Metab. 2012;97:E819-E829.
26. Boulkroun S, Samson-Couterie B, Golib-Dzib JF, Amar L, Plouin PF, Sibony M, Lefebvre H, Louiset E, Jeunemaitre X, Meatchi T, Benecke A, Lalli E, Zennaro MC. Aldosterone-producing adenoma formation in the adrenal cortex involves expression of stem/progenitor cell markers. Endocrinology. 2011;152:4753-4763.
27. Tauber P, Penton D, Stindl J, Humberg E, Tegtmeier I, Sterner C, Beuschlein F, Reincke M, Barhanin J, Bandulik S, Warth R. Pharmacology and pathophysiology of mutated KCNJ5 found in adrenal aldosteroneproducing adenomas. Endocrinology. 2014;155:1353-1362.